Business
Alvotech announces planned CEO succession and leadership transition
Photo of Lisa Graver Lisa Graver, incoming CEO of Alvotech - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver...
About this update from Alvotech
[{"type":"image","alt":"Alvotech","displaySize":"","headline":null,"caption":"Alvotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/47ab63b3b9a5dbfa19245a0e84094a11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YY_6xKylt6ihBQL0iyXywA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/47ab63b3b9a5dbfa19245a0e84094a11","width":300,"height":104}},"lazy":false},{"type":"text","content":"Photo of Lisa Graver","length":20,"tagName":"p"},{"type":"image","alt":"Lisa Graver, incoming CEO of Alvotech","displaySize":"","headline":null,"caption":"Lisa Graver, incoming CEO of Alvotech","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":960,"height":1212,"url":"https://media.zenfs.com/en/globenewswire.com/694c2f8b661afd2b0a8a2ba20757f9d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/77mS3UmueCcWBnpOk6.esg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyMTI7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/694c2f8b661afd2b0a8a2ba20757f9d0","width":960,"height":1212},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QsF6KywgLK2fYWThk2hf_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE5MjA7aD0yNDI0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/694c2f8b661afd2b0a8a2ba20757f9d0","width":960,"height":1212}}},{"type":"text","content":" - Róbert Wessman to continue serving as Executive Chairman in full-time capacity","length":80,"tagName":"p"},{"type":"text","content":"- Lisa Graver appointed Chief Executive Officer ","length":47,"tagName":"p"},{"type":"text","content":"REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company’s inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capacity. Lisa Graver has been appointed as his successor as Chief Executive Officer.","length":646,"tagName":"p"},{"type":"text","content":"“When I stepped into the CEO ro...